
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
LabCorp announced that its Covance Drug Development business will open a companion diagnostics lab in Morrisville, North Carolina.
The facility also includes a genomics and molecular pathology lab to support clinical trials and diagnostic testing development, and a nuclear magnetic resonance (NMR) laboratory that houses an NMR spectrometer, approved by the FDA. The site also houses manufacturing facilities for diagnostics materials and testing components.
Read the full release






